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Background: Exposure to ultrafine particles exerts diverse harmful effects including aggravation of pulmonary
diseases like asthma. Recently we demonstrated in a mouse model for allergic airway inflammation that
particle-derived oxidative stress plays a crucial role during augmentation of allergen-induced lung inflammation by
ultrafine carbon particle (UfCP) inhalation. The mechanisms how particle inhalation might change the inflammatory
balance in the lungs, leading to accelerated inflammatory reactions, remain unclear. Lipid mediators, known to be
immediately generated in response to tissue injury, might be strong candidates for priming this particle-triggered
change of the inflammatory balance.
Methods: We hypothesize that inhalation of UfCP may disturb the balance of pro- and anti-inflammatory lipid
mediators in: i) a model for acute allergic pulmonary inflammation, exposing mice for 24 h before allergen
challenge to UfCP inhalation (51.7 nm, 507 μg/m3), and ii) an in-vitro model with primary rat alveolar macrophages
(AM) incubated with UfCP (10 μg/1 x 106 cells/ml) for 1 h. Lungs and AM were analysed for pro- and
anti-inflammatory lipid mediators, namely leukotriene B4 (LTB4), prostaglandin E2 (PGE2), 15(S)-hydroxy-eicosatetraenoic
acid (15(S)-HETE), lipoxin A4 (LXA4) and oxidative stress marker 8-isoprostane by enzyme immunoassays
and immunohistochemistry.
Results: In non-sensitized mice UfCP exposure induced a light non-significant increase of all lipid mediators.
Similarly but significantly in rat AM all lipid mediators were induced already within 1 h of UfCP stimulation. Also
sensitized and challenge mice exposed to filtered air showed a partially significant increase in all lipid mediators. In
sensitized and challenged mice UfCP exposure induced highest significant levels of all lipid mediators in the lungs
together with the peak of allergic airway inflammation on day 7 after UfCP inhalation. The levels of LTB4, 8-isoprostane
and PGE2 were significantly increased also one day after UfCP exposure. Immunohistochemistry localized highest
concentrations of PGE2 especially in AM one day after UfCP exposure.
Conclusion: Our results suggest that UfCP exposure affects the balance between pro- and anti-inflammatory lipid
mediators. In allergic mice, where the endogenous balance of pro- and anti-inflammatory mediators is already
altered, UfCP exposure aggravates the inflammation and the increase in anti-inflammatory, pro-resolving lipid
mediators is insufficient to counterbalance the extensive inflammatory response. This may be a contributing
mechanism that explains the increased susceptibility of asthmatic patients towards particle exposure.
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Lipid mediators are involved in the onset, progression
and resolution of acute inflammation [1]. Tissue injury,
allergens or microbes activate formation and release of
arachidonic acid-derived lipid mediators, such as pros-
taglandins and leukotrienes, which regulate early events
in the inflammatory response. Those include changes
of blood flow, oedema and leukocyte recruitment. A
key feature of bioactive lipid mediators is the rapidity
with which they are synthesized; they appear within
minutes upon stimulation, as opposed to peptide med-
iators such as cytokines, which require hours to be
generated. By their specific receptors they mediate bio-
logical and physiological activities and gene expression
for a variety of inflammatory events [2-5]. At a later
time point counter-regulatory lipid mediators such as
lipoxins, resolvins and protectins, are generated to ini-
tiate the resolution of inflammation [6]. The resolution
of acute lung inflammation is an active process and
not merely characterized by the absence of pro-
inflammatory signals. The restoration of homeostasis is
coordinated by specific mediators and cellular events.
In response to inflammatory stimuli and injury, infil-
trating leukocytes and tissue-resident cells interact to
generate lipoxins, which are involved in the termin-
ation of inflammation [7].
Allergic asthma is a complex disorder of the conduct-
ing airways involving airway inflammation, declining air-
way function and hyperresponsiveness [8]. The
prevalence of asthma has rapidly increased over the last
few decades to epidemic proportions and is expected to
rise dramatically over the next 15–20 years [9,10].
Asthma is thought to arise from a complex interplay
of genetic susceptibility and environmental factors.
Epidemiological and clinical studies have shown an
association between increased ambient airborne particle
concentrations and adverse respiratory health effects,
leading to exacerbations of respiratory morbidity [11-13].
In particular, there is growing evidence that ultrafine
ambient particles play an important role in the patho-
genesis of respiratory diseases [14-16]. Ultrafine particles
(< 0.1 μm aerodynamic diameter) are characterized by a
high number concentration, low mass concentration and
a large surface area per mass [17]. Due to their small
size they have a higher deposition rate in the peripheral
lung compared to fine particles (< 2.5 μm aerodynamic
diameter) [18,19]. Primary ultrafine particles are formed
during gas-to-particle conversion or during incomplete
fuel combustion processes [20].
Ultrafine carbon particles (UfCP) exert an adjuvant
effect for allergen-induced lung inflammation [21].
Recently, we reported that the inhalation of UfCP
induced augmentation of oxidative stress in the
lungs of a mouse model for asthma in addition tolung inflammation, activation of nuclear factor κB,
cytokine release and airway hyperreactivity [22]. In
this follow up study we hypothesize that UfCP may
affect the balance between endogenous pro- and anti-
inflammatory and pro-resolving arachidonic acid-
derived lipid mediators. We therefore evaluated
concentrations of pro-inflammatory LTB4, immune-
modulating PGE2, anti-inflammatory 15(S)-hydroxytetraenoic
acid (15(S)-HETE), pro-resolving lipoxin A4 (LXA4)
and 8-isoprostane as marker for oxidative stress in two
different models: i) an in-vivo study with healthy mice
and in an allergic mouse model; and ii) an in-vitro
model with primary alveolar macrophages (AM) of
healthy rats as part of the primary pulmonary defence
system. We quantified the endogenous concentration of
lipid mediators in homogenates of AM and lung tissue
and determined immunohistochemically the localisation of
two of the mediators, PGE2 and 8-isoprostane, in lung tis-
sue and cells.Materials and methods
Materials
Phosphate-buffered saline (PBS) with and without Ca2+/
Mg2+ was purchased from Biochrome (Berlin, Germany);
RPMI was from PAA Laboratories (Linz, Austria); fetal calf
serum, penicillin, streptomycin and amphotericin were
from Life Technologies (Eggenstein, Germany); HEPES
(2-(4-(2-hydroxyethyl)-1-piperaziyl)-ethansulfonic acid) from
Sigma-Aldrich Chemie (Munich, Germany); all other che-
micals (analytical or HPLC grade) were from Merck
(Darmstadt, Germany).Ultrafine carbon particles (UfCP) exposure
Airborne UfCP were generated by electric spark dis-
charge (model GFG 1000, Palas, Germany) providing
aggregated carbon particles as previously described
[21,23,24]. UfCP average size distribution was character-
ized by a count median diameter of 51.7 nm, an average
mass median diameter of 84.7 nm and a geometric
standard deviation of 1.54. Temporal variability was
below 6.3% for all size distribution parameters. UfCP
exposures used for the in-vivo study were performed in
330 liter whole body exposure chambers with an air
exchange rate of 18.2 h-1 (100 lpm at an average dis-
placement velocity of 5 mm s-1) for 24 h.
Particle mass concentration was 507 μg m-3 (± 26) μg/m3,
which corresponds to an average particle number con-
centration of 9.3  106 cm-3 (± 0.6) cm-3. Temporal vari-
ability was below 5.1% for both number and mass
concentration. For the in-vitro study filter samples of the
UfCP (10 μg/ml) were suspended in liquid by ultrasonic
stirring and incubated with the cells for 60 min as
described later in more detail.
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Five to seven-week-old female Balb/c mice (Charles
River, Sulzfeld, Germany) and twelve- to −14-wk-old,
male Wistar Kyoto rats (WKY/Kyo@Rj; Janvier, France)
were housed in a humidity- (55% relative humidity) and
temperature- (22°C) controlled room in individually ven-
tilated cages (VentirackTM, cage type CU-31), main-
tained on a 12-h day/night cycle prior to the study.
Laboratory animal diet and water was provided
ad libitum. The studies were conducted under federal
guidelines for the use and care of laboratory animals
and were approved by the Government of the District of
Upper Bavaria and by the Helmholtz Zentrum Institu-
tional Animal Care and Use Committee.In vivo study with allergic mice
Allergen sensitization/challenge protocol
The animal study has been conducted as described pre-
viously [22]. In brief, BALB/c mice were sensitized by re-
petitive intraperitoneal injections of 1 μg OVA (Sigma,
grade VI)/Alum (Pierce, 2.5 mg) in phosphate buffered
saline (PBS with Ca2+/Mg2+) on days 0, 14, 28, 48, 72.
Blood samples were taken before and after sensitization.
OVA-specific IgE and IgG1 were measured in plasma
samples by ELISA as described previously [21].
OVA/albumin sensitized mice, compared to non sensi-
tized controls, were characterized by high titers of
OVA-specific IgE (31.7 ± 3.3 vs 0.1 ± 0.01 μg/ml) and
OVA-specific IgG1 (1178.4 ± 211.2 vs <0.1 μg/ml). On
day 86 the mice were aerosol-challenged for 20 min
with 1% OVA in PBS or with PBS alone delivered by
Pari-Boy nebulizer (Pari GmbH, Starnberg, Germany).
In order to minimize LPS contamination, the OVA so-
lution prepared for aerosol challenges was eluted over
polymyxin B columns (Endotoxin Detoxi-GelTM, Pierce
Chemical Co., Rockfort, IL, USA) according to the man-
ufacturer’s instruction.Study design
The mice were divided into 4 experimental groups: non
sensitized mice exposed to UfCP (UfCP group), OVA
sensitized mice exposed to filtered air 24 h prior to OVA
challenge (S/OVA group), OVA sensitized mice exposed
to UfCP 24 h prior to allergen challenge (S/UfCP/OVA
group), and age-matched untreated animals served as
baseline controls (untreated). Zero, 1, or 7 days after
OVA challenge or after termination of UfCP exposure,
BAL was performed as previously described [21]. After
BAL the right lobes of the lungs were snap frozen in li-
quid nitrogen and stored at −80°C for subsequent ana-
lysis (n = 4-9/time point). The left lobes of 2 lungs/time
point/group were fixed in 10% buffered formalin for
immunohistochemistry.In vitro study with primary rat alveolar macrophages
(AM)
Alveolar macrophages
AM from healthy WKY rats were isolated by bronchoal-
veolar lavage (BAL, repeated 5 times) using fresh ali-
quots of Ca2+/Mg2+-free PBS kept at 37°C. After 20 min
centrifugation at 400 x g cells were resuspended in RPMI
medium containing penicillin (100 U/ml), streptomycin
(100 U/ml), amphotericin (2.5 μg/ml) and 5% fetal calf
serum (further referred as RPMI medium). Viability was
about 97% as determined by trypan blue exclusion.
Microscopic examination after May Grünwald Giemsa
staining of cytospin preparations identified 95–100% of
the cells as AM.
Incubation of alveolar macrophages with particles
AM were incubated in RPMI medium with UfCP at a
mass concentration of 10 μg/1x106 AM/ml for 60 min at
37°C, corresponding to a specific surface area of 75 cm2/
1x106 AM/ml [23]. Control cells were incubated in par-
allel without particles. UfCP were prepared by electric
spark discharge (model GFG1000, Palas, Germany),
suspended in distilled water by repeated vortexing and
sonification [23] providing agglomerated carbon parti-
cles as previously described [23,24]. After incubation,
the cells were harvested by centrifugation 400 x g for
10 min at room temperature. The cell pellets were
resuspended in half of the incubation volume with cold
HEPES, pH 7.4, and homogenized by sonification (3
times, 15 s each time) in ice. The cell homogenates
were centrifuged at 10,000 x g for 15 min at 4°C. The
supernatants were taken for measurements of protein
and lipid mediators [25,26]. Analysis of the cell lysates
is a reliable tool to quantify the parameters in each
sample [25].
Analysis
Lipid mediators and protein determination
For analysis of lipid mediators, the supernatants of cell
or lung homogenates were used. Lung homogenates
(about 50 mg lung tissue/500 μl) were prepared by dis-
rupting lung tissue in HEPES, pH 7.4, with lysing matrix
E (FastPrep FP120 cell disrupter; MP Biomedicals
Germany GmbH, Eschwege, Germany). After centrifuga-
tion (3200 x g at 4°C for 10 min), aliquots of the
obtained supernatants were taken for determination of
protein and lipid mediators. Aliquots of supernatants
derived from cell homogenates of particle-treated cells
(prepared as described above) and those from lung
homogenates were deproteinized by adding 8-fold vol-
ume of 90% methanol containing 0.5 mM EDTA and
1 mM 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl, pH
7.4 [23]. These methanol suspensions were stored at −40°C




























































Figure 1 In-vivo study: BAL cell counts. Total counts of
neutrophils (A) alveolar macrophages (B) and eosinophils (C)
retrieved by bronchoalveolar lavage in the UfCP, S/OVA and S/UfCP/
OVA groups. Baseline levels which represent the data of the
untreated group (1,6 ± 1,9 for neutrophils, 90,2 ± 25,6 for AM and
0 ± 0 for eosinophils) are shown by a dotted line. Data presented as
mean± SD (n = 4–9 per time points for BAL cells. *p< 0.05 and
**p <0.01 vs baseline; +p< 0.05 and ++p <0.01 vs S/UfCP/OVA).
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proteins. Aliquots of the obtained supernatants were
dried in a vacuum centrifuge, dissolved in assay buffer,
and used for quantification of PGE2, LTB4 15(S)-HETE,
8-isoprostane and LXA4 by their specific enzyme immu-
noassays (Cayman Chemical Company, Ann Arbor, MI,
USA) according to the instructions of the manufacturer.
Protein was measured at 595 nm using 5 μl of homogen-
ate and 200 μl of 1:5 diluted Biorad solution (Bio-Rad,
Munich, Germany) with bovine serum albumin as
standard.
Immunohistochemistry
After formalin fixation and paraffin embedding, 5 μm
sections of the lungs obtained on day 1 and 7 were cut.
After deparaffinization the sections were placed in 0.1 M
citric acid, pH 6.0, and heated in a microwave at low
power for 15 min; immunostaining was performed
using an ABC-based method (Vector Laboratories,
Burlingame, CA) as previously described [27]. As pri-
mary antibodies, α-8-isoprostane and α-prostaglandin E2
were used (Oxford Biomedical Research, Oxford, MI,
USA). Negative controls included use of buffer alone or
respective dilutions of non-specific purified goat and
rabbit immunoglobulin G (IgG) in the primary layer
(Vector Laboratories).
Statistics
Statistical significance was determined by one-way ana-
lysis of variance with post-hoc Bonferroni test for the
in-vivo study and by analysis of variance and two-sample
Student`s t-test for the in-vitro study (STAT-SAK,
version2.12, by G. E, Dallal, 1986; Malden, MA).
Changes with P< 0.05 were considered as significant. A
regression analysis to test the association between lipid
mediators and cellular infiltration was performed with
Microsoft Excel 2010. R2 ≥ 0.5 were considered to indi-
cate weak and R2> 0.90 high correlation.
Results
In vivo study with healthy and diseased animals
To evaluate the effect of UfCP inhalation on the gener-
ation of endogenous lipid mediator in the lungs of
healthy and allergic mice we performed a further ana-
lysis of the study of Alessandrini et al. [22].
In Figure 1 we present the total cell counts of neutro-
phils, alveolar macrophages and eosinophils, obtained by
bronchoalveolar lavage after particle inhalation for each
group on each time point. In non-sensitized UfCP mice
there was no significant increase in all cell types on all
time points. However in the S/OVA group and the
S/UfCP/OVA group neutrophils, AM and eosinophils
increased significantly on day 7.Figure 2 describes the progression of each lipid medi-
ator with a pro-inflammatory (left) or with an anti-
inflammatory activity (right) on day 0, 1 and 7 after
particle exposure in non sensitized and sensitized mice.
On the pro-inflammatory side (Figure 2, left panel), com-
pared to baseline (untreated group), the levels of LTB4 in
the UfCP and S/OVA groups were elevated, although
non significantly, 2-3-fold at all time points after particle


































































































































































































Figure 2 In-vivo study: Effect of UfCP inhalation on pro-inflammatory (left) and anti-inflammatory (right) endogenous lipid mediator
levels in lung tissue of non sensitized and sensitized mice. Non sensitized mice were exposed to UfCP for 24 h (UfCP group) or kept in
filtered air (untreated group). OVA sensitized mice were exposed either to filtered air for 24 h and subsequently challenged with OVA (S/OVA
group), or to UfCP for 24 h and then challenged with OVA (S/UfCP/OVA group). At day 0, 1 and 7 after particle exposure/OVA challenge the
lungs were excised after BAL and used for analysis. The results are expressed in pg lipid mediator/mg protein analysed by specific enzyme
immunoassays: Left panel: LTB4 and 8-isoprostane (8-isoprostane reprinted with permission from 22); right panel: PGE2, 15(S)-HETE and LXA4.
Baseline values of untreated mice (dotted lines) are for LTB4: 264 ± 34 pg/mg; 8-isoprostane: 845± 231 pg/mg; PGE2: 34284± 4628 pg/mg;
15(S)-HETE: 1699 ± 189 pg/mg; LXA4: 125± 54 pg/mg. The data are given as absolute values (mean± SD), n = 4-9/time point; *p <0.05
and **p <0.01 vs baseline; +p <0.05 and ++p <0.01 vs S/UfCP/OVA.
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significantly increased at day 1 (p< 0.05 vs baseline)
reaching a 6-fold increase on day 7 (p< 0.01 vs base-
line). At this time point the increase in LTB4 in S/UfCP/
OVA was significant also compared to S/OVA and UfCP
(p< 0.01). In order to complete the set of data of pro-
inflammatory lipid mediators, the levels of 8-isoprostane,a lipid mediator used as a marker for oxidative stress,
were added in the present manuscript, although pub-
lished previously [22]. Its levels were significantly ele-
vated in S/UfCP/OVA 1 and 7 days after particle
inhalation and OVA challenge (3-fold). At day 1 the dif-
ference between UfCP and S/UfCP/OVA was significant
(p< 0.01).
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lipid mediators (Figure 2, right panel), high PGE2 base-
line levels in the lung of the untreated control group
could be further enhanced, although not significantly, on
day 1 and 7 after particle inhalation (up to 3-fold in
UfCP vs baseline). In S/OVA the increase of PGE2 on
day 7 was significant (p< 0.05 vs baseline, up to 5-fold).
In S/UfCP/OVA the PGE2 level increased significantly to
highest concentrations at day 1 and 7 (p< 0.01 vs base-
line, 9-fold on day 7). PGE2 levels in S/UfCP/OVA were
significantly increased compared to UfCP at day 1
(p< 0.05) and 7 (p< 0.01) and compared to S/OVA at
day 7 (p< 0.01). The levels of 15(S)-HETE in UfCP
were found to increase compared to baseline on day 1
after particle inhalation (3-fold), although not signifi-
cantly. In S/OVA 15(S)-HETE was found to be elevated
mainly on day 7 (up to 5-fold) and in S/UfCP/OVA at
day 1 and 7, where only at day 7 reached statistical
significance (p< 0.01 vs baseline and vs UfCP, up to
11-fold). Lastly, the levels of LXA4 in the UfCP
group increased 2-fold straight after particle inhal-
ation and decreased back to baseline levels thereafter.
In S/OVA and S/UfCP/OVA the levels of LXA4
increased at all time points, but reached statistical
significance only at day 7 (p< 0.05 vs baseline, withA
C
Figure 3 In-vivo study: Immunohistochemical analysis of 8-isoprostan
lung tissue was performed in formalin-fixed, paraffin-embedded mouse lun
(UfCP group), (C) sensitized and challenged mice exposed to filtered air (S/
challenge (S/UfCP/OVA group), retrieved 7 days after UfCP exposure/OVA c
cells; arrows indicate inflammatory cells including alveolar macrophages. Sca 3- and 4-fold increase, respectively). In S/UfCP/OVA
all mediators apart from 8-isoprostane significantly
increased from day 0 to day 7 (p< 0.01). In order to
test a possible association between lipid mediators and
cellular infiltration, we performed regression analysis.
We found a moderate correlation between neutrophil
numbers and PGE2 (day 1 time point, R
2 = 0.73), a weak
correlation between alveolar macrophages and PGE2
(day 7 time point, R2 = 0.50) and also correlations between
eosinophil numbers and LTB4, PGE2 and 15(S)-HETE
(day 7 time points, R2 = 0.72, R2 = 0.78 and R2= 0.59,
respectively). With the aim of evaluating the localization
of 8-isoprostane and PGE2 producing cells in the lungs
of non sensitized and sensitized mice, we performed
immunohistochemical analysis for 8-isoprostane and
PGE2 in lung sections retrieved 7 days after particle/
OVA inhalation (Figures 3 and 4 A-D, respectively).
Compared to the untreated controls with no detectable
staining (Figures 3A, 4A), the UfCP group (Figures 3B,
4B) showed a weak staining for 8-isoprostane and for
PGE2 in bronchial and bronchiolar epithelial cells and
an inconsistent staining in inflammatory cells including
AM (arrows), indicating a very mild inflammatory re-
sponse accompanied by low levels of oxidative stress. In
the S/OVA group (Figure 3C) 8-isoprostane stainingB
D
e in lung tissue. Immunohistochemical analysis of 8-isoprostane in
gs from: (A) untreated mice, (B) non sensitized mice exposed to UfCP
OVA group), and (D) sensitized mice exposed to UfCP prior to OVA
hallenge. Arrowheads indicate bronchial and bronchiolar epithelial




Figure 4 In-vivo study: Immunohistochemical analysis of PGE2in lung tissue. Immunohistochemical analysis of PGE2 in lung tissue was
performed in formalin-fixed, paraffin-embedded mouse lungs from: (A) untreated mice, (B) non sensitized mice exposed to UfCP (UfCP group),
(C) sensitized and challenged mice exposed to filtered air (S/OVA group), and (D) sensitized mice exposed to UfCP prior to OVA challenge
(S/UfCP/OVA group) retrieved 7 days after UfCP exposure/OVA challenge. (E) untreated mice, (F) sensitized and challenged mice exposed to
filtered air (S/OVA group), and (G) sensitized mice exposed to UfCP prior to OVA challenge (S/UfCP/OVA group) retrieved 1 day after UfCP
exposure/OVA challenge. Arrowheads indicate bronchial and bronchiolar epithelial cells; arrows indicate inflammatory cells including alveolar
macrophages. Scale bar, 50 μm.
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chial and bronchiolar epithelial cells (arrowheads) and in
inflammatory cells including AM (arrows). The PGE2
staining (Figure 4C) was similar, but more pronounced
compared to the same staining in the UfCP group.
S/UfCP/OVA revealed the strongest 8-isoprostane and
PGE2 staining localized in bronchial, bronchiolar (arrow-
heads) and alveolar epithelial cells and mainly in AM
(arrows) (Figures 3D, 4D). No 8-isoprostane or PGE2
staining were detected where control IgG was used in the
primary layer (data not shown).
Since the PGE2 levels in S/UfCP/OVA increased sig-
nificantly already at day 1 time point, while in S/OVA
remained close to UfCP (Figure 2, right panel), weperformed an immunohistochemical analysis for PGE2
of both groups at day 1 time point. Our results show a
strong difference between S/OVA and S/UfCP/OVA in
the PGE2 staining especially in AM, where AM from
S/UfCP/OVA stained more strongly compared to AM
from S/OVA (Figure 4F and G, respectively). This indi-
cates that AM are the first cells which drive the re-
sponse after particle inhalation.
In-vitro study with primary alveolar macrophages of
healthy animals
Since in S/UfCP/OVA AM showed a strong staining
for PGE2 already on day 1 after particle exposure
(Figure 4G), we decided to evaluate the effect of UfCP
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mediators as in the in-vivo study. As shown in Figure 5,
UfCP induced a significant increase in the production of
both pro-inflammatory (p< 0.05 vs control) and anti-
inflammatory lipid mediators (p< 0.01 for PGE2 and 15
(S)-HETE and p< 0.05 for LXA4) of about two-fold. The
data were given as absolute values to compare the con-
tribution of each lipid mediator in control and UfCP-
treated AM and to the in-vivo results. The levels of
PGE2 and especially 15(S)-HETE and LXA4 dominated













































Figure 5 In-vitro study: Effect of UfCP on the generation of endogeno
were incubated with UfCP (10 μg/1x106 cells/ml) for 60 min (UfCP group).
incubation, the cells were immediately homogenised. The cell lysates were
(upper panel), and of anti-inflammatory (lower panel) lipid mediators. The d
experiments (n = 4-6). *p <0.05 and **p <0.01 vs control.Discussion
In the present study we investigated the effect of UfCP
on the balance between the endogenous production of
pro- and anti-inflammatory and pro-resolving lipid med-
iators in an in-vivo model with healthy and allergic mice
and in an in-vitro model with AM from healthy animals.
We chose UfCP since there is growing evidence that
ultrafine ambient particles play an important role in the
pathogenesis of respiratory diseases [14,15,28]. Primary
ultrafine carbonaceous particles with a geometric diam-







us lipid mediator in primary rat alveolar macrophages. Rat AM
Control cells were incubated in parallel without particles. After
used for determination of the endogenous levels of pro-inflammatory
ata are given as absolute values (mean± SD) with n as number of
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was to compare data relative to particle induced-
synthesis of lipid mediators in-vivo and in-vitro, we have
quantified the concentrations of lipid mediators in abso-
lute values (pg mediator/mg protein) and we used simi-
lar particle concentrations/106 cells in the two systems.
In the in-vitro study we chose a particle concentration
(10 μg/1 x 106 AM/ml for 1 h incubation) which was op-
timal for eliciting production of lipid mediators in AM
known from our previous findings [23,31]. For the
in-vivo study, on the basis of a multiple path particle
deposition model [32], we estimated a total particle
mass deposition of 18.3 μg/mouse within 24 hrs using
standard breathing conditions and assuming rat and
mouse deposition probabilities to be similar. Consider-
ing adult mouse lungs to have a mean number of
2.9 (± 0.5) x 106 AM [33], we can estimate an amount
of 6.3 (± 1.1) μg UfCP/1 x 106 AM in the lungs of a
mouse for the 24 h in vivo exposure, not taking into ac-
count parameters like particle translocation or uptake
by different cell types [34]. Similarly, in the in-vitro
study, further parameters like cell-adherence, particle
sedimentary and diffusive transport rates or particle co-
agulation rates in the liquid environment are not con-
sidered. In total, we only have reason for the
assumption that exposure conditions in both studies
might be comparable from the particle mass available
per million of AM cells, which was 6.3 and 10 μg
UfCP/106 AM for the in-vivo and the in-vitro study,
respectively. In spite of any drawbacks, this may be a
first but significant hint for comparability.
One limitation of our study is that we did not use
AMs from control and sensitized mice for the in-vitro
study; we preferred to use primary AM of healthy rats,
because of the higher cellular yield in bronchoalveolar
lavage of an individual rat compared to that of a mouse.
UfCP are phagocytosed by AM and can be found in pha-
golysosomes of the cells [22,23,34]. The in-vitro study,
these particles exerted a significant stimulating effect on
all lipid mediators by about two-fold (Figure 5). Because
of the different baseline levels of the single mediators,
the involvement of each mediator contributed, depending
on its concentration, to the outcome of the AM response
by the particles. In the inflammatory reactions induced
by the particles the properties of immune-modulating
PGE2, anti-inflammatory 15(S)-HETE and pro-resolving
LXA4 (Figure 5, lower panel) dominated the mediator
profile compared to pro-inflammatory LTB4 and oxida-
tive stress marker 8-isoprostane (Figure 5, upper panel)
and could counterbalance the effect of LTB4 and oxida-
tive stress. This is consistent with our previous in-vitro
findings showing an inhibiting effect of UfCP-treated AM
on the respiratory burst activity of stimulating neutro-
phils [31]. When particle-treated AM were pre-incubatedwith indomethacin (i.e. an inhibitor for cyclooxygenase
and therefore also for PGE2 production), the down-
regulating effect of the particles on the respiratory burst
activity of stimulated neutrophils was abolished. Recently
we have shown with primary canine and human AM that
UfCP activated cytoplasmatic phospholipase A2 (cPLA2),
the initial enzyme for the production of lipid mediators,
liberating arachidonic acid from membrane phospholi-
pids (see Figure 6; [23]). We also observed this in rat
AM (data not shown). Moreover we showed that arachi-
donic acid was metabolised to the different mediators by
cyclooxygenase to PGE2, by 15-lipoxygenase to 15(S)-
HETE [25], and by 5-lipoxygenase to LTB4. In addition
arachidonic acid was oxidized to 8-isoprostane by non-
enzymatic oxidation indicating that the particles induced
oxidative stress reactions in the cells. This was due to
the oxidative potential of the particles; we found that
particles were able to oxidise the amino acid methionine
to methionine sulfoxide, and that they showed an ESR
signal equivalent to a free radical within the particle core
[23]. The pro-resolving mediator LXA4 also increased
during particle incubation, which is in agreement with
our recent findings with human neutrophils [35]. LXA4
is generated via PGE2 and 15(S)-HETE and represents a
stop signal for inflammation to return the inflamed tissue
to homeostasis [36].
In non-sensitized mice, inhalation of UfCP alone
induced a light, non significant increase of all mediators,
apart from LXA4 (Figure 2). LTB4 is a potent chemo-
attractant for neutrophils [37], but the increase of
LTB4 following particle exposure alone did not provoke
an influx of neutrophils (Figure 1). Obviously, the
particle-induced production of LTB4 seems to be too
low to induce a neutrophil influx into the lungs. PGE2
and 15-HETE showed higher baseline levels compared
to the other mediators, as previously described for
PGE2 [2] and consequently showed the highest produc-
tion after particle exposure. We have previously shown
that particle exposure induces a transient and moder-
ate NF-κB activation and TNF-α expression [22,38].
We can speculate that healthy mice respond to particle
exposure with a very light and transient inflammation
due to the dominating endogenous levels of immune-
modulating PGE2 and anti-inflammatory 15(S)-HETE,
probably supporting the suppression of pro-inflammatory
mediators including LTB4. Our in-vivo and in-vitro find-
ings show a similar immune-modulating/anti-inflamma-
tory response to particle exposure in AM from healthy
rats and in lung tissue from healthy mice.
In sensitized mice, exposure to allergen challenge
alone (S/OVA group) induced a significant increase of
PGE2 and LXA4 compared to untreated control
(Figure 2). Although the endogenous levels of PGE2
and 15(S)-HETE (up to 5-fold on day 7) again
Figure 6 Schematic representation of arachidonic acid-derived lipid mediators. Particles and/or OVA challenge interfere with cell
membranes to activate cytoplasmatic phospholipase A2 (cPLA2), which cleaves arachidonic acid from membrane phospholipids. Due to the
oxidative potential of UFCP [23], arachidonic acid is non-enzymatically oxidized to 8-isoprostane, used as a marker for redox imbalance.
Arachidonic acid serves as a substrate for the downstream pathways of COX (cyclooygenase), 15- and 5-LO (15- and 5-lipoxygenase), leading to
formation of prostaglandins such as PGE2, 15(S)-HETE, leukotrienes such as LTB4 and to LXA4 via PGE2 activated 15-LO [23,26,35]. Because these
processes are predominantly located in the nuclear membrane or perinuclear space, these products of these pathways may influence gene
expression. LTB4 activates the inflammation, whereas PGE2, 15(S)-HETE and LXA4 are immune-modulating, anti-inflammatory and pro-resolving
lipid mediators, respectively.
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counterbalance the allergen-induced inflammation.
The analysis of the lipid mediators in sensitized ani-
mals exposed to UfCP inhalation only (without OVA
challenge) was not performed since both at the func-
tional and at the BAL cell infiltration level the re-
sponse was not different compared to NS/UfCP
[21,22]. In S/UfCP/OVA, exposure to UfCP before al-
lergen challenge increased significantly the levels of
all mediators. These data were confirmed by our
immunohistological studies showing increased staining
for 8-isoprostane and for PGE2 in S/OVA (Figures 3C
and 4C) compared to healthy controls, which
increased further in S/UfCP/OVA (Figure 3D for 8-
isoprostane and Figure 4D for PGE2). In addition, the
immunohistochemical analysis of PGE2 on day 1
revealed a very strong staining for PGE2 mainly in
AM of S/UfCP/OVA vs S/OVA (Figure 4E to G). We
therefore suggest, that AM are the first cells driving
the force for the particle-induced early inflammatory
responses.PGE2 is known as an immune-modulator and exerts
its action by binding to one or to a combination of its
four subtypes of receptors EP1, EP2, EP3 and EP4 [39].
The EP receptors are expressed on the nuclear mem-
branes of cells. They are functional due to modulation of
gene transcription providing an additional role of PGE2
in the regulation of cell functions [40]. Furthermore,
cyclooxygenase-2 derived prostaglandins, including
PGE2, are not only involved in the onset of inflamma-
tion but serve also an important role in the resolution
of inflammation. This is due to the ability of PGE2 to
induce 15-lipoxygenase expression for production of
15(S)-HETE thus promoting the biosynthesis of lipoxins
such as LXA4 [41,42]. In a model of acute lung injury,
selective COX-2 inhibition or deficiency results in pro-
longed inflammation by decreasing production of PGE2
and pro-resolving mediators including LXA4 [41,43].
We have recently reported that PGE2 is able to modu-
late iron oxide particle-induced inflammation in a
model of healthy rat AM in-vitro. Depending on size
and surface area per mass, small iron oxide particles
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induced a high endogenous level of PGE2 in AM which
suppressed the release of the pro-inflammatory cytokine
IL-6 [25]. In contrast, larger iron oxide particles (diam-
eter: 1.5 μm; specific surface area: 7.1 m2/g) induced
only a moderate endogenous level of PGE2 which was
not able to prevent the IL-6 release. In a parallel con-
ducted in-vivo study with healthy rats the larger parti-
cles caused an inflammation in the lung, whereas the
smaller particles did not [25]. These findings underline
the immune-modulating and anti-inflammatory proper-
ties of PGE2. The relative high concentrations of PGE2
released in S/UfCP/OVA were not able to counteract
the allergic inflammatory response. An interesting paper
from Martin et al. [44] reported for a rat model of aller-
gic asthma that external PGE2, administered in concen-
trations of 1 to 3 μg by intratracheal insufflation 30 min
before OVA challenge, inhibited the early and late re-
sponse of pulmonary resistance and reduced the
bronchoalveolar levels of eosinophils and cysteinyl-
leukotrienes. The authors concluded that PGE2 is a po-
tent inhibitor of allergic airway responses in a rat model
of allergic asthma. However, in our study we measured
the endogenous levels of all lipid mediators. Concerning
the endogenous PGE2 levels at day 7, S/OVA showed
with 0.165 μg PGE2/mg protein an about 20 times lower
level and S/UfCP/OVA with 0.3 μg PGE2/mg protein a
10 times lower level than the externally added PGE2
concentrations (1 to 3 μg) in the study of Martin et al.
[44]. We therefore suggest that the endogenous levels
of immune-modulating PGE2 and anti-inflammatory
15(S)-HETE were not high enough to counterbalance the
endogenous levels of pro-inflammatory LTB4 and other
inflammatory mediators during the allergic inflammation.
Also the pro-resolving mediator LXA4 was unable to
contribute to a reduction of the severe inflammatory re-
sponse in the S/OVA and S/UfCP/OVA groups probably
because of its low endogenous levels (Figure 2, right
panel). On the contrary, high endogenous levels of LTB4
in S/UfCP/OVA were accompanied by a strong increase
of neutrophils, although the regression analysis at single
animal level for this association in all experimental
groups did not have enough power to detect a correl-
ation (R2< 0.25), (Figures 1 and 2). The inflammatory
response was accompanied by an increase in oxidative
stress as indicated by the increase in 8-isoprostane deter-
mined by its specific analysis and by immunohistochem-
istry. The inflammation was probably supported by the
high amounts of eosinophils in the lungs of S/OVA,
which increased even more by the particle exposure in
S/UfCP/OVA, as shown in Figure 1. Eosinophils contrib-
ute to allergen-induced lung inflammation by producing
cysteinyl leukotrienes, derived via activation of 5-
lipoxygenase, and eosinophil cationic protein [45-47].Furthermore, it is known from the blood of patients
with severe asthma that decreased levels of LXA4 are
coexisting with increased ones of LTB4 and cysteinyl
leukotriens [48]. Interestingly, we obtained a strong
correlation (R2> 0.7) between BAL eosinophils and
LTB4 or PGE2 levels in the lungs. Recently it was
shown, that AM of patients with non-severe and severe
asthma contained lower levels of LXA4 than those of
normal individuals resulting in a pro-inflammatory im-
balance [49]. Moreover, the airway levels of LXA4 and
the expression of its biosynthetic enzymes, including
cyclooxygenase-2 and 15-lipoxygenase, and the LXA4
receptor were markedly decreased in severe asthma
[50]. We did not observe a decrease in anti-
inflammatory mediators following allergen challenge
probably because our mouse model is characterized by
mild allergic inflammation and lacks the changes in the
inflammatory milieu that are described in severe
asthma models.
In a recent study in our mouse allergy model, inhal-
ation of ultrafine carbon particles prior to OVA chal-
lenge caused most significant changes in Clara cell
protein CC16 in BALF and serum, BALFs total protein
and TNF-α expression in lung homogenates and the
strongest morphological alterations of Clara cells and
goblet cell metaplasia in sensitized mice compared to
non-sensitized mice [38]. The data suggest that in the al-
lergic mice the mechanisms to compensate the altera-
tions of Clara cells and globlet cell metaplasia due to
particle exposure are insufficient [38]. All these observa-
tions support the concept of an insufficient role of the
anti-inflammatory lipid mediators in counterbalancing
the strong inflammatory responses.
Conclusion
Particle exposure increased the release of endogenous
lipid mediators, and affected their pro- and anti-
inflammatory balance, both in our in-vivo and in-vitro
studies. In AM and lung tissue of healthy animals
immune-modulating/anti-inflammatory PGE2, anti-
inflammatory 15(S)-HETE and pro-resolving LXA4
dominated the lipid mediator profile and thus contribute
to dampen the already mild inflammatory response
caused by particle exposure. On the contrary, the expos-
ure of allergic mice to particle inhalation (S/UfCP/OVA)
aggravated further the already ongoing inflammation of
the allergic mice, shifting the endogenous balance
strongly to pro-inflammatory responses. Although PGE2
and 15(S)-HETE were still present in high amounts,
their endogenous levels were not sufficient to counter-
balance the inflammation. Since UfCP represent the core
of diesel exhaust particles [29,30], our data suggest an
aggravation of allergen-induced lung inflammation by
environmental particles.
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